A Phase 2 interventional study of Autogene cevumeran and Pembrolizumab in Advanced Melanoma, sponsored by Genentech, Inc.. Completed at 41 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Melanoma by Hoffmann-La Roche — none open to participants now, 4 under way, none of them phase 3. Melanoma · Hoffmann-La Roche.
Among the 57 studies in Melanoma by Hoffmann-La Roche, this one is the 17th largest by enrollment of the 52 interventional ones that give a count, is one of 4 that started in 2018, is one of 15 in phase 2, and was the 48th registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →None of the 57 studies in Melanoma by Hoffmann-La Roche is open now. The open studies under Melanoma, anywhere →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 18 · Phase 3 7 · Phase 4 1
First in 2004; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 131 is above the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 53 across the 52 interventional studies, 339 across the 5 observational. Of the 52 that completed or were terminated, 34 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
3 of the studies in Melanoma by Hoffmann-La Roche that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04835805Genentech, Inc.A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. | 2026-12-31 |
| NCT04140500Hoffmann-La RocheDose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors | 2027-06-30 |
| NCT02568267Hoffmann-La RocheBasket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 57 studies in Melanoma by Hoffmann-La Roche, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy, safety, pharmacokinetics, and patient-reported outcomes (PROs) of autogene cevumeran (RO7198457) plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive at least one cycle of 200 mg pembrolizumab monotherapy by intravenous (IV) infusion followed by 200 mg pembrolizumab IV infusion every 3 weeks (Q3W) plus a recommended dose of autogene cevumeran.
Biological: Autogene cevumeran · Drug: Pembrolizumab
Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W. Participants in Arm A have the option to cross over to combination treatment with autogene cevumeran plus pembrolizumab (Arm B) after confirmed disease progression.
Drug: Pembrolizumab
Participants will receive at least one cycle of 200 mg pembrolizumab monotherapy by IV infusion followed by 200 mg pembrolizumab IV infusion Q3W plus a recommended dose of autogene cevumeran.
Biological: Autogene cevumeran · Drug: Pembrolizumab
Participants will receive a recommended dose of autogene cevumeran administered by IV infusion at protocol-defined intervals.
Also known as: RO7198457
Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W.
Also known as: Keytruda
Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v.1.1) After Randomization
PFS was defined as the time from randomization to the first documented PD as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). Kaplan-Meier (KM) method was used to estimate median PFS.
Time frame: From randomization to PD or death (up to approximately 60 months)
Objective Response Rate (ORR) According to RECIST V.1.1 After Randomization
ORR was defined as the percentage of participants with a complete response (CR) or a partial response (PR) on two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to RECIST v1.1. CR was defined as the disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off to the nearest whole number.
Time frame: Up to approximately 60 months
Overall Survival (OS) After Randomization
OS was defined as the time from randomization to death from any cause. KM method was used to estimate the median OS.
Time frame: From randomization to death (up to approximately 63 months)
Duration of Response (DOR) According to RECIST V.1.1 After Randomization
DOR was defined as the time from the first occurrence of a documented objective response (OR) to PD or death from any cause, whichever occurred first, as determined by the investigator according to RECIST v1.1. CR was defined as the disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. DOR was estimated using the KM methodology.
Time frame: Up to approximately 60 months
Change From Baseline in Global Health Status (GHS)/Health-related Quality of Life (HRQoL) Score Assessed by European Organisation for Research and Treatment of Cancer 30-Item Quality of Life Questionnaire (EORTC QLQ-C30)
EORTC QLQ-C30 consists of 30 questions that assess participant functioning (physical, emotional, role, cognitive, and social), symptom scales (fatigue, nausea and vomiting, pain), GHS/QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Change in HRQoL was assessed using participant responses to questions regarding GHS (Question 29: GHS; "How would you rate your overall health during the past week?") and QoL (Question 30: QoL; "How would you rate your overall quality of life during the past week?") and were scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores were standardized. Scores range from 0-100. A higher score indicates a better QoL.
Time frame: Baseline, Day 1 of Cycles 1 to 34, time of first PD, time to last dose, treatment discontinuation and study drug completion (up to approximately 29 months) (1 cycle = 21 days)
ORR According to RECIST V.1.1 After Crossover
ORR was defined as the percentage of participants with a CR or PR on two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR.
Time frame: Up to 54.7 months
Number of Participants With Adverse Events (AEs)
An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.
Time frame: Baseline up to 90 days after the final dose of study drug (Safety run-in and randomized stage: up to 32 months; Cross-over stage: up to 24 months)
A total of 131 participants with previously untreated advanced melanoma took part in the study at 40 investigative sites across the United States, Germany, Australia, Spain, Belgium, and the United Kingdom from 21 December 2018 to 21 January 2025. The study consists of an initial safety run-in stage followed by a randomized stage (Arm A \& Arm B). Participants in Arm A had an option to crossover to Arm B after confirmed disease progression (PD), if crossover eligibility criteria were met.
| Milestone | Safety Run-in | Arm A: Pembrolizumab | Arm B: Pembrolizumab + RO7198457 | Crossover: Pembrolizumab + RO7198457 |
|---|---|---|---|---|
| Started | 6 | 0 | 0 | 0 |
| Safety-evaluable (se) population | 6 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 6 | 0 | 0 | 0 |
| Withdrew: Death | 2 | 0 | 0 | 0 |
| Withdrew: Study ended by sponsor | 4 | 0 | 0 | 0 |
| Milestone | Safety Run-in | Arm A: Pembrolizumab | Arm B: Pembrolizumab + RO7198457 | Crossover: Pembrolizumab + RO7198457 |
|---|---|---|---|---|
| Started | 0 | 41 | 84 | 0 |
| Se population | 0 | 44 | 80 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 41 | 84 | 0 |
| Withdrew: Death | 0 | 13 | 29 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 4 | 0 |
| Withdrew: Study ended by sponsor | 0 | 14 | 42 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 | 9 | 0 |
| Withdrew: Discontinued due to pd to receive cross-over treatment | 0 | 10 | 0 | 0 |
| Milestone | Safety Run-in | Arm A: Pembrolizumab | Arm B: Pembrolizumab + RO7198457 | Crossover: Pembrolizumab + RO7198457 |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 10 |
| Se population | 0 | 0 | 0 | 10 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 10 |
| Withdrew: Death | 0 | 0 | 0 | 2 |
| Withdrew: Study ended by sponsor | 0 | 0 | 0 | 7 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
PFS was defined as the time from randomization to the first documented PD as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). Kaplan-Meier (KM) method was used to estimate median PFS.
| months | Arm A: Pembrolizumab | Arm B: Pembrolizumab + RO7198457 |
|---|---|---|
| Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v.1.1) After Randomization | 7.9 (2.8 to 22.7) | 8.3 (6.9 to 26.9) |
ORR was defined as the percentage of participants with a complete response (CR) or a partial response (PR) on two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to RECIST v1.1. CR was defined as the disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off to the nearest whole number.
| percentage of participants | Arm A: Pembrolizumab | Arm B: Pembrolizumab + RO7198457 |
|---|---|---|
| Objective Response Rate (ORR) According to RECIST V.1.1 After Randomization | 48.8 (32.26 to 65.30) | 41.7 (30.53 to 52.80) |
OS was defined as the time from randomization to death from any cause. KM method was used to estimate the median OS.
| months | Arm A: Pembrolizumab | Arm B: Pembrolizumab + RO7198457 |
|---|---|---|
| Overall Survival (OS) After Randomization | NA (19.6 to NA) | 62.2 (41.8 to NA) |
DOR was defined as the time from the first occurrence of a documented objective response (OR) to PD or death from any cause, whichever occurred first, as determined by the investigator according to RECIST v1.1. CR was defined as the disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. DOR was estimated using the KM methodology.
| months | Arm A: Pembrolizumab | Arm B: Pembrolizumab + RO7198457 |
|---|---|---|
| Duration of Response (DOR) According to RECIST V.1.1 After Randomization | NA (19.8 to NA) | NA (36.1 to NA) |
EORTC QLQ-C30 consists of 30 questions that assess participant functioning (physical, emotional, role, cognitive, and social), symptom scales (fatigue, nausea and vomiting, pain), GHS/QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Change in HRQoL was assessed using participant responses to questions regarding GHS (Question 29: GHS; "How would you rate your overall health during the past week?") and QoL (Question 30: QoL; "How would you rate your overall quality of life during the past week?") and were scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores were standardized. Scores range from 0-100. A higher score indicates a better QoL.
| score on a scale | Arm A: Pembrolizumab | Arm B: Pembrolizumab + RO7198457 |
|---|---|---|
| Baseline | 64.74 ± 24.67 | 73.39 ± 21.56 |
| Change at Cycle 1 Day 1 | — | 0.00 ± 0.00 |
| Change at Cycle 2 Day 1 | -1.85 ± 17.72 | -1.37 ± 14.40 |
| Change at Cycle 3 Day 1 | 2.60 ± 16.73 | 0.54 ± 16.69 |
| Change at Cycle 4 Day 1 | 3.74 ± 16.45 | -3.70 ± 19.48 |
| Change at Cycle 5 Day 1 | 3.53 ± 19.32 | -1.84 ± 15.56 |
| Change at Cycle 6 Day 1 | 0.00 ± 20.57 | -6.03 ± 22.51 |
| Change at Cycle 7 Day 1 | 2.27 ± 15.04 | -1.01 ± 15.85 |
| Change at Cycle 8 Day 1 | 0.83 ± 10.08 | 0.15 ± 18.35 |
| Change at Cycle 9 Day 1 | -2.92 ± 12.76 | -1.19 ± 15.77 |
| Change at Cycle 10 Day 1 | 4.39 ± 14.26 | -3.72 ± 15.43 |
| Change at Cycle 11 Day 1 | 0.52 ± 16.52 | 1.06 ± 14.29 |
| Change at Cycle 12 Day 1 | 1.56 ± 13.34 | -4.07 ± 14.82 |
| Change at Cycle 13 Day 1 | 1.11 ± 24.57 | 0.00 ± 13.61 |
| Change at Cycle 14 Day 1 | 2.98 ± 12.49 | -2.03 ± 13.54 |
| Change at Cycle 15 Day 1 | 0.56 ± 13.16 | -3.07 ± 16.37 |
| Change at Cycle 16 Day 1 | 0.64 ± 16.12 | -1.72 ± 15.04 |
| Change at Cycle 17 Day 1 | 4.86 ± 15.27 | -2.60 ± 15.62 |
| Change at Cycle 18 Day 1 | 5.00 ± 18.51 | -4.57 ± 17.72 |
| Change at Cycle 19 Day 1 | 0.00 ± 19.64 | -1.61 ± 14.18 |
| Change at Cycle 20 Day 1 | 5.56 ± 11.79 | -1.67 ± 14.42 |
| Change at Cycle 21 Day 1 | 9.26 ± 12.80 | -0.31 ± 15.41 |
| Change at Cycle 22 Day 1 | 11.46 ± 12.55 | -1.79 ± 17.18 |
| Change at Cycle 23 Day 1 | 8.33 ± 9.32 | -2.68 ± 17.43 |
| Change at Cycle 24 Day 1 | 2.78 ± 13.82 | -3.87 ± 22.28 |
| Change at Cycle 25 Day 1 | 1.85 ± 18.53 | -4.81 ± 18.59 |
| Change at Cycle 26 Day 1 | 5.21 ± 14.04 | -3.40 ± 14.85 |
| Change at Cycle 27 Day 1 | 0.00 ± 8.91 | -2.47 ± 15.64 |
| Change at Cycle 28 Day 1 | -4.76 ± 20.89 | -2.67 ± 17.47 |
| Change at Cycle 29 Day 1 | 2.08 ± 14.60 | -2.47 ± 15.98 |
| Change at Cycle 30 Day 1 | -1.04 ± 5.34 | -7.69 ± 17.47 |
| Change at Cycle 31 Day 1 | 3.13 ± 14.73 | -3.67 ± 18.65 |
| Change at Cycle 32 Day 1 | 7.29 ± 14.39 | -3.21 ± 18.72 |
| Change at Cycle 33 Day 1 | 5.21 ± 13.32 | -4.81 ± 18.59 |
| Change at Cycle 34 Day 1 | 7.29 ± 13.68 | -5.00 ± 18.16 |
| Change at Time of First PD | -1.47 ± 26.06 | -4.17 ± 19.43 |
| Change at Time of Last Dose | -5.65 ± 25.40 | -7.30 ± 23.55 |
| Change at Treatment Discontinuation | -2.27 ± 26.75 | -11.07 ± 18.43 |
ORR was defined as the percentage of participants with a CR or PR on two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR.
| percentage of participants | Crossover: Pembrolizumab + RO7198457 |
|---|---|
| ORR According to RECIST V.1.1 After Crossover | 40.0 (4.64 to 75.36) |
An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.
| Participants | Safety Run-in | Arm A: Pembrolizumab | Arm B: Pembrolizumab + RO7198457 | Crossover: Pembrolizumab + RO7198457 |
|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs) | 6 | 43 | 79 | 10 |
Collected over Baseline up to 90 days after the final dose of study drug (Safety run-in and randomized stage: up to 32 months; Cross-over stage: up to 24 months); All-cause Mortality: up to approximately 63 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Safety Run-in | 2/6 (33.3%) | 3/6 (50%) | 6/6 (100%) |
| Arm A: Pembrolizumab | 14/44 (31.8%) | 16/44 (36.4%) | 40/44 (90.9%) |
| Arm B: Pembrolizumab + RO7198457 | 30/80 (37.5%) | 25/80 (31.3%) | 78/80 (97.5%) |
| Crossover: Pembrolizumab + RO7198457 | 3/10 (30%) | 4/10 (40%) | 9/10 (90%) |
| Event | Safety Run-in | Arm A: Pembrolizumab | Arm B: Pembrolizumab + RO7198457 | Crossover: Pembrolizumab + RO7198457 |
|---|---|---|---|---|
| ChillsGeneral disorders | 1/6 | 0/44 | 0/80 | 0/10 |
| CholecystitisHepatobiliary disorders | 1/6 | 0/44 | 0/80 | 0/10 |
| Cytokine release syndromeImmune system disorders | 1/6 | 0/44 | 2/80 | 1/10 |
| Device related infectionInfections and infestations | 1/6 | 0/44 | 0/80 | 0/10 |
| Enteritis infectiousInfections and infestations | 1/6 | 0/44 | 0/80 | 0/10 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/6 | 5/44 | 3/80 | 0/10 |
| DuodenitisGastrointestinal disorders | 0/6 | 0/44 | 0/80 | 1/10 |
| DeathGeneral disorders | 0/6 | 0/44 | 0/80 | 1/10 |
| Liver function test abnormalInvestigations | 0/6 | 0/44 | 0/80 | 1/10 |
| Small intestine carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/6 | 0/44 | 0/80 | 1/10 |
| Event | Safety Run-in | Arm A: Pembrolizumab | Arm B: Pembrolizumab + RO7198457 | Crossover: Pembrolizumab + RO7198457 |
|---|---|---|---|---|
| FatigueGeneral disorders | 5/6 | 13/44 | 36/80 | 5/10 |
| Infusion related reactionInjury, poisoning and procedural complications | 0/6 | 2/44 | 62/80 | 5/10 |
| NauseaGastrointestinal disorders | 3/6 | 11/44 | 22/80 | 2/10 |
| Influenza like illnessGeneral disorders | 3/6 | 4/44 | 14/80 | 1/10 |
| Cytokine release syndromeImmune system disorders | 3/6 | 0/44 | 2/80 | 1/10 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/6 | 7/44 | 20/80 | 2/10 |
| HypertensionVascular disorders | 2/6 | 5/44 | 9/80 | 4/10 |
| HypothyroidismEndocrine disorders | 2/6 | 2/44 | 9/80 | 1/10 |
| ChillsGeneral disorders | 2/6 | 1/44 | 3/80 | 1/10 |
| Oedema peripheralGeneral disorders | 2/6 | 1/44 | 7/80 | 0/10 |
Intent-to-treat (ITT) population included all randomized participants.
| Age, Continuous(years) | Safety Run-in | Arm A: Pembrolizumab | Arm B: Pembrolizumab + RO7198457 | Total |
|---|---|---|---|---|
| Mean | 63.3 ± 11.0 | 62.4 ± 14.4 | 63.6 ± 14.2 | 63.2 ± 14.0 |
| Sex: Female, Male(Participants) | Safety Run-in | Arm A: Pembrolizumab | Arm B: Pembrolizumab + RO7198457 | Total |
|---|---|---|---|---|
| Female | 1 | 11 | 27 | 39 |
| Male | 5 | 30 | 57 | 92 |
| Ethnicity (NIH/OMB)(Participants) | Safety Run-in | Arm A: Pembrolizumab | Arm B: Pembrolizumab + RO7198457 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 | 2 |
| Not Hispanic or Latino | 6 | 39 | 69 | 114 |
| Unknown or Not Reported | 0 | 1 | 14 | 15 |
| Race (NIH/OMB)(Participants) | Safety Run-in | Arm A: Pembrolizumab | Arm B: Pembrolizumab + RO7198457 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 1 |
| White | 6 | 38 | 80 | 124 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 3 | 2 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from Dec 2018 to primary completion in Jan 2025, 73 months.
Results were first posted in Jan 2026, 1 year after primary completion.
Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 73 months is above that.
Counting every sponsor, half of 384 studies reached it within 53 months; a quarter within 32 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Autogene cevumeran